Bromantane

Bromantane
Clinical data
Trade names	Ladasten
Other names	Bromantan; Bromontan; ADK-709; Adamantylbromphenylamine
Routes of; administration	Oral (tablets)
ATC code	None;
Legal status
Legal status	US: Unscheduled not FDA approved; Rx-only (RU);
Pharmacokinetic data
Bioavailability	27.5%
Elimination half-life	11.21 hours (in humans),; 7 hours (in rats)
Identifiers
	IUPAC name N-(4-Bromophenyl)adamantan-2-amine;
CAS Number	87913-26-6 ;
PubChem CID	4660557;
ChemSpider	3849628 ;
UNII	N1ILS53XWK;
CompTox Dashboard (EPA)	DTXSID40405333 ;
ECHA InfoCard	100.213.907
Chemical and physical data
Formula	C16H20BrN
Molar mass	306.247 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C1C2CC3CC1CC(C2)C3NC4=CC=C(C=C4)Br;
	InChI InChI=1S/C16H20BrN/c17-14-1-3-15(4-2-14)18-16-12-6-10-5-11(8-12)9-13(16)7-10/h1-4,10-13,16,18H,5-9H2 ; Key:LWJALJDRFBXHKX-UHFFFAOYSA-N ;
	(what is this?) (verify)

Bromantane, sold under the brand name Ladasten, is an atypical psychostimulant and anxiolytic drug of the adamantane family related to amantadine and memantine which is used in Russia in the treatment of neurasthenia. Although the effects of the bromantane have been determined to be dependent on the dopaminergic and possibly serotonergic neurotransmitter systems, its exact mechanism of action is unknown, and it is distinct in its properties relative to typical psychostimulants such as amphetamine. Because of its unique aspects, bromantane has sometimes been described instead as an actoprotector.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.